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Abstract
Background: As a major public health issue in China and worldwide, late-life depression is associated with
physical limitations, greater functional impairment, increased utilization and cost of health care, and suicide. Like
other chronic diseases in elders such as hypertension and diabetes, depression is a chronic disease that the new
National Health Policy of China indicates should be managed in primary care settings. Collaborative care, linking
primary and mental health specialty care, has been shown to be effective for the treatment of late-life depression
in primary care settings in Western countries. The primary aim of this project is to implement a depression care
management (DCM) intervention, and examine its effectiveness on the depressive symptoms of older patients in
Chinese primary care settings.
Methods/Design: The trial is a multi-site, primary clinic based randomized controlled trial design in Hangzhou,
China. Sixteen primary care clinics will be enrolled in and randomly assigned to deliver either DCM or care as usual
(CAU) (8 clinics each) to 320 patients (aged ≥ 60 years) with major depression (20/clinic; n = 160 in each treatment
condition). In the DCM arm, primary care physicians (PCPs) will prescribe 16 weeks of antidepressant medication
according to the treatment guideline protocol. Care managers monitor the progress of treatment and side effects,
educate patients/family, and facilitate communication between providers; psychiatrists will provide weekly group
psychiatric consultation and CM supervision. Patients in both DCM and CAU arms will be assessed by clinical
research coordinators at baseline, 4, 8, 12, 18, and 24 months. Depressive symptoms, functional status, treatment
stigma and clients’ satisfaction will be used to assess patients’ outcomes; and clinic practices, attitudes/knowledge,
and satisfaction will be providers’ outcomes.
Discussion: This will be the first trial of the effectiveness of a collaborative care intervention aiming to the
management of late-life depression in China primary care. If effective, its finding will have relevance to policy
makers who wish to scale up DCM treatments for late-life depression in national wide primary care across China.
Study Registration: The DCM project is registered through the National Institutes of Health sponsored by clinical
trials registry and has been assigned the identifier: NCT01287494
Background
Depression is predicted to be the illness with the great-
est negative impact and disease burden by the year 2020
[1]. Late-life depression affects approximately 8% to 16%
of community-dwelling older adults in the U.S. [2], mak-
ing it the most common mental health disorder of later
life. Late-life depression is associated with physical
limitations, greater functional impairment, increased uti-
lization and cost of healthcare, and increased suicide
and all-cause mortality [3]. Late-life depression also
represents a major public health issue in China. In the
city of Beijing, the 1-year prevalence of geriatric depres-
sion was 4.33% [4], and among patients in general hos-
pitals in Shenyang the rate is 11% [5]. Rates of
depression are even higher for patients with chronic dis-
eases, (i.e., 78.9%) [6]. The total estimated cost of
depression in China for 2002 is US$6.3 billion [7].
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mary care settings for the treatment of depression,
because most depressed individuals visit their primary
care physicians (PCPs) during the course of their
depressive episode [8]. Combinations of pharmacologic
and psychosocial interventions currently available to
PCPs have been shown to effectively treat patients with
depression in primary care [9,10]. In Western countries,
over one-half of all depression is treated in PC clinics
[11]. The growth of available antidepressants, such as
selective serotonin reuptake inhibitors (SSRIs), has made
it safer and easier for PCPs to treat depression [12].
Given the low rates of older adults who seek specialty
mental health services [13], it is crucial that PCPs place
a high priority on recognizing and treating older
patients with depression.
In 2006, the central government of China published
guidelines on the development of community health ser-
vices. They designated primary care a central compo-
nent of the new strategy, with health education and
promotion, outpatient evaluation, and case management
of chronic disease and physical rehabilitation as the
major responsibilities of primary care [14].
PC clinics in China have several advantages as a set-
ting for mental health care delivery [15]. First, the con-
venience of PCC for elders: in most urban areas,
residents can find a PC clinic within a half-mile radius
around his/her house. Second, higher rates of insurance
coverage: government health insurance covers a greater
proportion of care when delivered through the PC sys-
tem (90-100%) compared to care delivered in hospitals
(70-100%). Third, PCC is responsible for the manage-
ment of chronic disease: in each PCC, there are physi-
cians and nurses for whom chronic disease management
(e.g., diabetes) is a familiar activity. PC providers in
these clinics are equipped to treat and manage chronic
disease due to their training background and responsi-
bilities according the new National Health Policy. Mean-
while, mental disorders are considered chronic diseases
that also should be managed in primary care settings in
the new National Health Policy of China [16]. Depres-
sion is a form of chronic disease due to its frequently
relapsing and recurring course, making it a natural fit
with the new emphasis on chronic disease management.
Fourth, less stigma and fewer barriers to access: Epide-
miological studies have shown that the Chinese had
lower rates of late life depression compared with Wes-
terns [17]. However, the over-65 age group has the
highest rate of completed suicide, reaching 44.3-200 per
100 000 [18], which is four to five times higher than the
Chinese general population; and depression is a major
cause of suicide among older adults [19]. Chinese cul-
ture, stigma, and a tendency to express depression
somatically in Chinese elders make them reluctant to
seek care from mental health specialists [20,21]. Indivi-
duals may be more likely to seek treatment for mental
health problems in a primary care setting [22], as less
stigma is associated with primary care treatment com-
pared to mental health care clinics in China, just as in
the West [23].
Despite the potential role for primary care in the man-
agement of depression, low levels of detection and treat-
ment of depression have been highlighted in primary
care settings [24]. A range of patient, doctor and prac-
tice barriers contribute to the under-recognition and
less than optimal management of depression in primary
care settings: at the patient level, comorbidity and reluc-
tance to speak about depressive symptoms; at the provi-
der level, PCPs’ lack of knowledge and skill; and at the
practice level, lack of adequate consultation time and
insufficient access to specialized mental health resources
[25-27]. Up to 80% of patients with a diagnosable
depressive or anxiety disorder present with somatic
complaints, which may affect PCPs’ ability to recognize
and diagnose depression or anxiety [28]. Patients’ lim-
ited awareness regarding depression and its frequent
manifestation through nonspecific physical symptoms,
especially in China is also an important barrier to accu-
rate diagnosis of depression [27,29,30]. Depressed
patients with higher stigmatized beliefs regarding mental
health are less adherent to pharmacologic treatments
[31,32]. For PCPs, knowledge and skills appear to influ-
ence the recognition and appropriate management of
depression [33]. PCPs who demonstrate better concep-
tual understanding of mental illness also demonstrate
greater diagnostic accuracy [34]. The specific beliefs and
attitudes that PCPs hold toward depression also appear
to impact upon their diagnosis and management of
depression [35].
Based on the principles of the Chronic Disease Man-
agement Model, and derived from successful research
conducted in patients with depression, the “collaborative
care model (CCM)” for depression in adults and older
adults has sufficient evidence for dissemination and
implementation [36,37]. The CCM for depression is not
a single intervention or set of interventions, but a prin-
ciple-guided approach to the treatment and manage-
ment of depression. Interventions that can be classified
as CCM can range from simple telephone interventions
to encourage compliance with medication [38] to com-
plex interventions at the “systems level.” The prototypi-
cal ingredients of CCM at the systems level include the
following: 1) a multi-professional approach to patient
care, 2) activated patients, 3) a structured patient man-
agement plan (e.g., recognition and assessment of
depression, psychoeducation, treatment guidelines, mon-
itoring of outcomes), 4) scheduled patient follow-up,
and 5) enhanced inter-providers communications
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have demonstrated that when treatment guidelines (TG)
are integrated into a practice with a multifaceted and
longitudinal treatment approach, significant improve-
ments in guideline-concordant care and patient out-
comes result [40-48]. This research indicates that the
three classes of professionals integral to CCM are 1)
PCPs, 2) care managers, and 3) mental health specialists
[49].
Objectives
Based on chronic disease management theory and pre-
vious CCM studies in western countries, we propose to
test a Depression Care Management (DCM) interven-
tion, which includes TG to support PCPs management
of depression in their older patients; primary care nurses
as care managers (CM) to monitor the progress of treat-
ment, support patient’s adherence, educate patients/
family and facilitate communication between providers;
and psychiatrists to provide consultation and supervision
of care managers. Using a randomized controlled design,
we will examine whether the DCM is an effective treat-
ment for patients with late life depression in urban
China. The primary outcome would be the improvement
of depressive symptoms of patients in primary care
setting.
Our specific aims are:
1) To determine whether the DCM intervention
results in improved outcomes compared with care as
usual (CAU) at patient levels (e.g., greater reduction in
depressive symptoms);
2) To determine whether the DCM intervention
results in improved outcomes compared with care as
usual (CAU) at provider level (e.g., greater adherence to
quality indicators);
3) To compare DCM with CAU with regard to a
range of outcomes in other pertinent domains, both at
the provider (e.g., improvements in knowledge/attitudes)
and patient (e.g., functioning, satisfaction) levels.
The DCM trial is a collaborative effort between insti-
tutions in China. The lead institution is the Department
of Psychology Zhejiang University, whiles the partner
organizations are the Department of Psychiatry Univer-
sity of Rochester Medicine Center, the Department of
Psychiatry Chinese University of Hong Kong, the
Department of Health in Hangzhou City, the Mental
Health Center of Hangzhou City. The study protocol
was approved by the Human Study Committee in Chil-
dren Hospital of Zhejiang University (OHRP IRB
#00003806).
Methods/Design
Study design: Two-stage screening and randomized-con-
trolled trial comparing collaborative depression care
management (DCM) to care as usual (CAU) in the
treatment of late life depression.
All older adult patients who receive care at participat-
ing clinics will be approached by clinic administrative
personnel with the opportunity to participate in the first
stage of depression screening (who will obtain verbal
consent to release the patient’s contact information to
the study team). The first stage of screening involves
completion of a depression screening tool (i.e., PHQ-9)
in order to maximize efficiency of time allocation for
study personnel. Only patients who score above the
study-determined threshold on the PHQ-9 (see below)
will be invited to participate in the second stage of
screening (i.e., structured diagnostic clinical interview).
Study location
The study will take place in 16 PCCs in Hangzhou City.
In the urban area of Hangzhou City, there are 185 pri-
mary care clinics (PCCs) [50] providing services for 4.19
million residents (16% of them aged ≥ 60 in 2008) [51].
Each clinic: 1) has 1-2 doctors and 3-4 nurses, 2) is
funded by the district government and supervised by a
primary care center in this district, 3) does not include
an inpatient service or university affiliation, 4) provides
care for 8,000-12,000 residents. The routine service of
each PCC involves provision of the following [52]: 1)
outpatient medical care, 2) preventive medicine, 3)
chronic disease management (currently only two dis-
eases: hypertension and diabetes), 4) health education,
5) physical rehabilitation, 6) family planning.
Sixteen of the 30 PCCs in the Shangcheng District will
be randomly selected and assigned to the DCM inter-
vention condition or the control condition (i.e., CAU).
a) Assignment will be by a remote computer-generated
number sequence concealed from researchers. b)
Included PCCs will be informed of their assignment to
DCM or CAU after patients are enrolled in the study by
research interviewers. c) The randomization will be at
the clinic level (i.e., rather than patient level).
Study conditions: CAU and DCM
CAU: Current practice, when depression is detected
by PCPs, involves suggesting to patients (or family
members) that they consult a mental health institution
for diagnosis and treatment. There is no direct referral/
transfer mechanism between PCPs and mental health
specialists. Occasionally PCPs prescribe antidepressants
following mental health specialists’ protocols on
patients’ medical records. To evaluate the potential
effectiveness of the DCM intervention, information is
needed on patients in the CAU as well as DCM. For
ethical reasons PCPs in both groups will be informed of
the screening results (i.e., depression diagnoses from the
structured clinical interviews). In previous studies, iden-
tification of depression alone or usual referral has been
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This indicates that there is very low possibility that pro-
viding diagnostic data to CAU PCPs will diminish the
hypothesized differences between the two groups. How-
ever, the provision of this diagnostic information does
go beyond usual care practices, thus indicating that
“enhanced care as usual” would be the most precise
descriptor for our control condition. For ease of com-
munication, however, we will refer to our control condi-
tion as CAU.
DCM intervention
Treatment guidelines (TG): The Depression Manage-
ment Toolkit [58] used in the Three-Component Model
(TCM) for late life depression will be translated and
adapted for use with Chinese PCPs. Provided to us by
the MacArthur Initiative for Depression in Primary Care
the toolkit includes recognition and diagnostic informa-
tion, patient education materials, treatment information,
and monitoring and follow-up information. In addition
to translation, the adaptations in this study are the treat-
ment guidelines and the management approach for
treating depression. With the improvement of treatment
and antidepressants in recent years, the adaptation of
TG for late life depression is necessary. The Duke
Somatic Treatment Algorithm for Geriatric Depression
(STAGED) was designed for geriatric depression [59]
and all drugs in the STAGED are now readily accessible
in China. We will adapt the STAGED to just two stages:
1) 8 weeks treatment with sertraline, 2) another 8 weeks
treatment augmentation with bupropion if patients fail
to respond in the initial trial. For more complicated
cases, the transfer to psychiatrists is indicated. We need
to provide PCPs’ with a simple, straightforward treat-
ment protocol because they have essentially no mental
health training. With the adaption and integration from
the STAGED approach, we will utilize two of the treat-
ment approaches in DCM: the “antidepressant medica-
tions” and the “mental health referral”.C u r r e n t l y ,t h e
provision of psychological counseling by Chinese PCPs
and nurses is not feasible due to their training back-
ground. Results from our preliminary studies indicate
that only 12.7% of PCPs felt confident in the delivery of
evidence-based psychotherapy. The medication treat-
ment protocol is listed below:
PCPs allocated in the DCM intervention group will
treat recruited patients with medication treatment for
16 weeks.
1). Initial trial: Patients with major depression will
receive an 8-week initial trial of sertraline. The initial
daily dose will 25 mg (a.m.) and increased a week later
to 50 mg (a.m.). The dose can be increased to 100 mg/
day at Week 3 and 150 mg/day at Week 6. Study physi-
cians will have the option of changing the dosage by 25
mg increments if the patient reports difficulties with
side effects. The maximum dosage allowed is 150 mg/
day. Sertraline is efficacious in reducing depressive
symptoms, safe, and well tolerated by patients with or
without medical illness [60]. Given current practices in
PCCs in China, it is not expected that patients will
request alternative medications; however, should this
issue arise, patient choice will be respected (when feasi-
ble) and this departure from the algorithm will be noted
in clinical monitoring forms.
2). Second stage: If the initial trial produces a good
response (50% decrease in score on PHQ-9 from base-
line to Week 6), the sertraline treatment will last
another 8-weeks. If patients fail to respond in the initial
trial, patients will receive an 8-week trial of sertraline
augmentation with bupropion with the psychiatrist’s
consultation. After unsuccessful treatment with an initial
SSRI, bupropion provides a reasonable second-step
choice for patients with depression [61]. We will not
provide PCPs the option of switching to venlafaxine due
to studies documenting risk for cardiovascular side
effects for patients with late life depression using Venla-
faxine [62-64].
3). Follow-up: Patients treated under the above proto-
col will be followed by care managers. During follow-up,
the care manager will administer the PHQ-9, SSI, side
effects scale, and record of adherence to recommenda-
tions (see Measures section below for descriptions). At
16 weeks, patients who are either asymptomatic or have
minimal depressive symptomatology will receive conti-
nuation treatment, while patients with clinically signifi-
cant depressive symptoms and signs (<30% decrease in
score on HAMD from baseline to Week 16) will be
referred for psychiatric consultation.
4). Continuation treatment: Patients who are asympto-
matic or have minimal symptoms after 16 weeks treat-
ment with Sertraline alone or augment with Bupropion
will receive continuation treatment for 6 months and be
followed by CRCs through telephone contact. The
dosage of Sertraline or/and Bupropion will be the same
as the above treatment phase. After the continuation
treatment, patients will discontinue or continue their
medications with psychiatric consultation.
Care managers (CM): In this study, primary care
nurses in the primary care clinics (PCCs) will be
employed as care managers for these reasons: 1) there
are not enough mental health specialists in Chinese pri-
mary care settings; 2) PCPs will not accept outside pro-
viders working with them on a regular basis; 3) there is
a full-time nurse in all PCCs in the study location who
is assigned to chronic disease (including hypertension
and diabetes) management for older patients in primary
care. Adding the depression management care to their
existing responsibilities will facilitate implementation of
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jobs in the primary care system; 4) nurses in PCCs are
familiar with many older patients in the neighborhood,
thus promoting higher acceptability to patients relative
to case managers outside the community; 5) nurses’
clinical knowledge regarding medication side effects,
their ability to treat chronic disease, and their ability to
establish rapport with PCPs are also advantages for care
management; 6) care managers who can coordinate the
care delivered by mental health specialists and PCPs-
including nurses-will best be able to sustain their ser-
vices, regardless of their specific clinical training [24].
Although the lack of specific knowledge and skills on
late life depression representing a major barrier for the
use of nurses as care managers, we will draw upon the
care manager manualized training and toolkit for nurse
in the TCM studies-that has demonstrated effectiveness
[65-68]. After training, care managers will acquire skills
to: 1) score the PHQ-9 to assess symptoms and severity
of depression both initially and in follow-up contacts; 2)
use focused questions to evaluate suicide risk; 3) use
patient education materials to promote adherence to the
management protocols; 4) Conduct initial and all subse-
quent care management calls; 5) complete CM reports
to effectively communicate call outcomes and patient
status to PCPs; 6) prepare forms for efficient care man-
agement supervision with the supervising psychiatrist.
And the communication between the professionals and
care managers in the DCM intervention will be facili-
tated by: 1) a weekly case conference including psychia-
tric consultants, 2) weekly case management
supervision, 3) communication forms between providers,
4) patients’ tracking forms for the intervention and its
progress.
Psychiatrists: The clinical complexities of treating
severe depressive episodes and episodes occurring
simultaneously with various physical illnesses often lead
PCPs and care managers to consult with mental health
specialists. In our study, a psychiatrist will conduct
weekly group supervision of care managers and PCPs in
a 1-hour case conference (for each DCM clinic). The
resources and backup they provide for the PCPs will
allow the PCPs to be more confident in managing
patients with late life depression. The supervision for
PCPs and care managers has been demonstrated to be
an important component determining the effectiveness
of a CCM [69].
Two psychiatrists with over 10 years of clinical prac-
tice experience, will offer enhanced mental health sup-
port for PCPs and care managers. Psychiatrists will
perform three major services: 1) supervising CM, 2) pro-
viding informal consultation to PCPs, 3) increasing the
quantity and quality of mental health referral resources.
T h ew e e k l y1 - h o u rc a s ec o n f e r e n c ef o ra l lP C P sa n d
case managers in the DCM intervention group will be
an approach for delivering these services. The confer-
ence will be held at PCCs.
Participants’ recruitment and intervention
Older Adult Research participants: All contacts with pri-
mary care doctors in 16 PCCs may be utilized for
research. These are older adults (aged ≥ 60) who are liv-
ing in the community and contact the primary care doc-
tors in this community for their physical health care.
Data collected by specialists at initial contact may come
either from the older adults him/herself or from his/her
family. Care managers and research personnel will col-
lect data from the older adult him/herself. The inclusion
and exclusion criterion are listed below:
Inclusion Criteria: 1) Age ≥ 60 years: The retirement
age is 60 years old for most people in China, and they
will be regarded as older people. 2) Community-dwelling
residences: Subjects must be registered residents of the
community, and thus also of the community’sP C C .W e
will not recruit older patients in hospitals or other
health institutes, and no temporary residents (e.g.,
migrants). Institutionalized patients are different from
primary care patients on screening, diagnosis and treat-
ment strategies. Less than 2% of older residents in the
community are temporary; they are not eligible for rou-
tine care in the PCCs and it is very difficult to track
their medical records. 3) Capable of independent com-
munication: The ability of independent communication
is necessary for the 1-2 hours interview and baseline in-
depth assessment, it is also necessary for telephone con-
tact and follow-up with the care managers. Hearing or
vision problems are very common in older people. If
subjects have vision problems but can hear and under-
stand the conversation in person and by telephone, they
will be included. If a subject has mild or moderate hear-
ing problems but can communicate with hearing aids,
they will also be included. 4) Mini-Mental State Exami-
nation (MMSE) score ≥18: As depression is associated
with cognitive impairment, inclusion of patients with
mild cognitive problems is important to this study. But
if patients have moderate to severe cognitive impairment
(as indicated by ≤17 on the MMSE) on the initial assess-
ment, the reliability of self-reported information
obtained from these patients would be expected to be
low, and PCPs may have greater difficulty in treating the
complicated case with comorbidity of depression and
dementia.
Exclusion Criteria: 1) Incapable of giving written
informed consent to this study: Patients who are unable
to comprehend the purpose and procedures of the
study, appreciate the risks and alternative, or agree to
the study for irrational reasons will be considered
unable to sign consent. We will test their capacity to
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sent form as presented by the research assistant prior to
enrollment. 2) Acute high suicide risk at baseline assess-
ment: If patients are found to be at acute high suicide
risk based on the psychiatrist’s assessment at intake,
they need immediate intervention such as referral to
mental health specialists or informing patients’ relatives.
They will be excluded from the study at that time.
Patients assessed to be dangerously suicidal at later
assessments after enrollment will be discontinued from
the study (an outcome measure of interest), their provi-
ders notified, and their safety guaranteed. 3) Psychosis:
We exclude patients with psychosis to ensure our ability
to test the proposed hypotheses. Few older adults (3.4%)
have heavy alcohol drinking in urban China; and the
current rate of alcohol abuse in elderly is lower than 1%
[70-72]. Therefore we will not exclude subjects on that
basis.
The flow of participants in the trial
Administrative staffs in each PCC administer the PHQ-9
screening program before patients’ visit with doctors. In
the allocated 16 PCCs, all patients who screen ≥10 on
the PHQ-9 will be invited to participant in our study.
After the verbal consent to release their contact infor-
mation to the study team, patients’ name and contact
information will be provided to Clinical Research Coor-
dinator (CRC) who will contact patients and invite them
to participate in the second stage of screening, the
structured diagnostic interview.
A CRC will initiate contact with recruited patients and
introduce our study (aims, procedures, risks and bene-
fits). The CRC will obtain informed consent for the
diagnostic interview. After written informed consent is
obtained, a psychiatrist who is blind to the study design
will conduct a diagnostic interview and in-depth assess-
ment of recruited patients. The interview will take place
in patients’ homes or in the PCCs’ offices at the
patients’ discretion.
After completion of the baseline diagnostic interview,
eligible participants (i.e., those with major depression)
who consent to participation will be assigned CAU or
DCM based on which PCC they receive care from (see
Figure 1). If patients present with acute suicide risk, psy-
chosis, or severe cognitive impairment during the base-
line assessment (i.e., exclusion criteria for the study),
their PCP and family will be notified, and they will be
given a referral for mental health specialists.
Every physician in the DCM intervention condition
will receive a “paper case” a week before the training
program (a training case adapted from the Depression
Management Tool Kit in TCM studies). The 2.5-h train-
ing program chaired by the investigator will be con-
ducted in each clinic. PCPs will be trained to use the
depression medication algorithm based on the STAGED
guidelines, provided with the skills needed for use of a
depression diagnosis and response measure, and
instructed in the use of communications forms and rou-
tines. Finally, physicians will be trained on how to fill
the Clinical Record Form (CRF) for this study.
D4. Measures
D4.a At the patient level: We will gather information
about age, gender, education, marital status, living con-
ditions and satisfaction with their economic status, as
well as systematic information on suicidal ideation, psy-
chopathology, medical health, cognitive function, quality
of life and stigma and satisfaction for the treatment.
D4.b At the provider level: the objective of research
measures at the provider level is to gather social-demo-
graphic data such as age, gender, education, marital sta-
tus, clinical experience among physicians in the
participating PCCs as well as systematic information on
their attitudes/knowledge regarding depression and clin-
ical practices with the treatment guidelines.
Almost all assessment instruments-both patient and
provider level-are currently in use in China. The sche-
dule of administration of these measures is summarized
in Table 1.
Outcomes assessment
Patient’s level
1) Depression - The Mood Disorder Module of the
Structured Clinical Interview for DSM-IV (SCID-MD),
will be used to derive intake depressive diagnoses [73]
and the Hamilton Rating Scale for Depression (HDRS,
17-item version) will be used to measure depressive
symptom severity [74]. The Chinese version of SCID
has good inter-rater reliability: the overall percentage
agreement for principal diagnoses was 80%, which
improved to 87% when only psychiatric patients were
considered [75]. The reliability and validity of the Chi-
nese version of the 17-item HDRS has been investigated
and is supported [76].
2) Suicidal ideation: The Scale for Suicidal Ideation
(SSI) [77] will be used to assess current suicidal ideation.
The Chinese version of the Geriatric Suicide Ideation
Scale (GSIS-C), the adaptation of the SSI to be used in
the current study, demonstrated excellent internal con-
sistency. In terms of convergent validity, the GSIS-C
correlated significantly and positively with depression
(assessed by CES-D), loneliness (assessed by Revised
UCLA Loneliness Scale), and hopelessness (assessed by
Beck Hopelessness Scale) [78].
3) Cognition function: The objectives of this assess-
ment are to provide a measure of cognitive dysfunction
and identify cognitive impairments that may associated
with depression or/and development of dementia. The
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a commonly used, well validated, rapidly administered
global measure of cognitive function. The Chinese ver-
sion of MMSE showed a sensitivity of 77% and specifi-
city of 70%[80] on diagnoses of dementia.
4) Anxiety: The Clinical Anxiety Scale (CAS) [81] will
be used to assess anxiety symptoms. CAS is a 6-item
scale derived from the Hamilton Anxiety Scale (HAMA)
after deletion of items overlapping with depression.
Research supports the reliability and validity of scores
derived from the Chinese version of the CAS [82].
5) Medical health: The Cumulative Illness Rating Scale
(CIRS)[83], a reliable and validated measure of medical
burden that quantifies the amount of pathology in each
organ system, will be use to assess subjects’ medical
health status. In our preliminary studies, we translated
a n du s e dt h eC I R S .A f t e rt h e manual training, inter-
rater reliability was 0.95.
6) Quality of life: The 12-item Short-Form Health Sur-
vey (SF-12) [84] is a commonly used measure of quality
of life (QOL). The Chinese version of SF-36 functioned
in general population of Hangzhou quite similarly to the
original American version, with comparable, and ade-
quate, internal consistency and test-retest reliability. The
Cronbach’s a coefficients ranged from 0.72 to 0.88 for
the social functioning scale and 0.66 for the vitality
scale. Two weeks test-retest reliability coefficients ran-
ged from 0.66 to 0.94 [85].
7) Treatment Stigma (TS): To assess patient’ss t i g m a
regarding medication treatment for depression, three
items will be used. The 3 questions which are adapted
from Givens’ study [86], include: If I were taking a pre-
scribed medication for depression: a) I would feel
ashamed (yes/no), b) I would feel comfortable telling my
friends or family(yes/no), and c) I would feel okay if
people in my community knew(yes/no).
8) Satisfaction: The Client Satisfaction Questionnaire
8-item (CSQ-8) [87,88] is regularly used to assess
patient’s satisfaction with their service utilization. The
psychometric characters of CSQ-8 have been
Figure 1 Participants Recruitment Flowchart. (Key: PC-primary care, CRC- clinic research coordinator, DCM- depression care management,
CAU- care as usual)
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as the CSQ-18, and often better. The authors report
high internal consistency (Cronbach’s alpha coefficient >
0.8) and this scale successfully distinguishes degrees of
satisfaction even at high levels of satisfaction. We will
translate and adapt it specifically for our study. We will
assess patients’ satisfaction with their treatment in PCCs
via the CSQ-PCC.
Providers’ level
1) Social-demographic: General information including
age, gender, education, and martial status will be
assessed, and number of years worked in PCCs, which
may affect physicians’ adherence, will also be assess to
be used as a co-variate in all analyses.
2) Clinical practices: The Practice Questionnaire (PQ)
will be used to be as a standardized document to measure
providers’ adherence to treatment guidelines. The PQ
includes four questions: a) If clinicians prescribe Sertra-
line (Yes/No)? b) If clinicians document an evaluation of
suicidal risk (Yes/No)? c) If clinicians provide an appoint-
ment for follow-up (Yes/No)? d) If clinicians transfer a
complicated patients to a mental health specialist (Yes/
No)? We will design a Clinical Record Form for the spe-
cific rating of patient symptoms, side effects and clinician
medication strategy for recording providers’ practice. We
will also use the medical records (MR) to track providers’
clinical practices, including antidepressant prescriptions,
documented evaluations of suicide risk, and provision of
an appointment for follow-up.
3) Attitudes/knowledge: The Depression Attitude
Questionnaire (DAQ) [89] will be administered at
baseline to assess PCPs’ attitudes/knowledge regarding
depression, and administered at the conclusion of the
study to quantify changes in attitudes/knowledge after
participating in DCM. The DAQ has been used to assess
PCPs’ attitudes/knowledge towards depression in differ-
ent countries [90,91]. The author of the DAQ has pro-
vided us with the Chinese version of DAQ.
4) Satisfaction: We will assess providers who are in the
DCM intervention arm on their satisfaction with the
DCM program via the CSQ-DCM. The CSQ-DCM will
be adapted from the CSQ and be specific to this study
protocol.
Other outcomes of interest
The ultimate goal of the intervention is to improve the
full range of adverse outcomes associated with depres-
sion in later life. While depression symptom severity
and associated quality of care indicators are our focus,
we also will track psychiatric hospitalizations, incident
suicide attempts, and deaths due to suicide and other
causes. These outcomes will be too infrequent in a
study this size to allow for statistical comparison, but
will be useful for descriptive purposes and planning for
future, larger scale studies.
Data management and analysis
Data management
Forms will be created for the encoding of data. The
forms will be available as hard copy and as computer-
based forms to allow direct encoding of data during
subject interviews. These data will be stored in the
Department of Psychology in Zhejiang University using
Table 1 Summary table of data collection in DCM trial
Level Assessment Baseline 4 months 8 months 12 months 18 months 24 months
Patient SDQ √
SCID √
HDRS √√ √ √ √ √
SSI √√ √ √ √ √
CAS √√ √ √ √ √
SF-12 √√ √ √ √ √
MMSE √√ √
CIRS √√ √
TS √√ √ √ √
CSQ-PCC √√ √ √ √
Provider SDQ √
DAQ √√ √ √ √ √
PQ √√√
CSQ-I √√√ √ √
Key: SDQ-Social Demographic Questionnaire; SCID–Structured Clinical Interview for DSM-IV; HDRS-24-item Hamilton depression scale; SSI-Scale for Suicidal
Ideation; CAS-Clinical anxiety scale; SF-12-12-item Short-Form Health Survey; MMSE-Mini-Mental State Examination; CIRS-Cumulative Illness Rating Scale; TS-Stigma
on Medication treatment for Depression; CSQ-P-Client Satisfaction Questionnaire for all patients in PCCs; DAQ-Depression Attitude Questionnaire; PQ-Practice
Questionnaire, based on the Clinical Record Form and Medical Records in the authorized administration system; CSQ-I-Client Satisfaction Questionnaire for all
providers in DCM and CAU intervention.
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with biostatistics and programmers). Program proce-
dures (as developed with Biostatistics) ensure adequate
error checking, security safeguards, and computer back-
ups. Biostatistician collaborators primarily use SPSS for
data analysis. Records of subject contacts will be kept by
the Program Manager on personal computers using
Excel software.
Statistical Analysis
The power analysis takes advantage of the longitudinal
design for the repeatedly measured outcomes such as
depression symptom severity. We assume an average
correlation of 0.5 among three follow-up assessments.
W ef u r t h e ra s s u m ead r o p - o u tr a t eo fu pt o1 5 %b a s e d
on prior similar studies. Finally, we adjusted the sample
size to accommodate the nesting of patients within
clinics (given the patient is the unit of analysis and ran-
domization is at the clinic level). Our experience with
nested study data in similar settings show that the intra-
class correlation (ICC) has varied from close to 0 to
0.05. Our analyses will assume the higher ICC of 0.05
(lower ICCs will result in greater power). With 16
clinics (8 randomized to CAU and 8 to DCM) and 20
depressed subjects from each clinic, we will have a sam-
ple of 320 depressed subjects with 160 per treatment
condition.
The sample size of 320 will allow detection of an aver-
age between-group effect size of about 0.37 for continu-
ous outcomes over the three follow-up assessments for
the repeatedly measured outcomes such as depressive
symptoms. Effect sizes for major depression in PCP care
ranges from 0.17 to 1.1 based on a meta-analysis study
[92]. Thus, the proposed sample is sufficiently powered
to detect clinically meaningful changes in this primary
outcome of interest.
The sample size will also detect an odds ratio of about
1.8 for the analysis of the binary outcome of remission
status; with an estimated remission rate of 0.6 for the
intervention group and a squared multiple correlation of
0.3 among the covariates. Similarly, we will be able to
detect an odds ratio of 1.7 for the treatment condition
in the analysis of the binary outcome of adherence to
treatment guidelines with an estimated rate of 0.7 for
the intervention group and a squared multiple correla-
tion of 0.3 between the covariates. Odds ratios for
adherence for depressed patients in PCP care ranges
from 1.3 to 5.6 based on a meta-analysis study [93]. The
proposed sample size is sufficient to detect clinically
meaningful changes in adherence to treatment guide-
lines for our study. Note that since data on adherence is
collected longitudinally over the assessments and power
was computed based on a cross-sectional design, the
detectable odds ratio 1.7 is conservative and even a
smaller odds ratio can be detected.
General Considerations for Data Analysis
Prior to hypotheses testing, we will conduct prelimin-
ary analyses to assess whether random assignment of
physicians to groups produces groups that are compar-
able with respect to demographic and baseline clinical
conditions. Measures of demographic characteristics
and outcomes at baseline will be examined using t-
(for continuous variables) or chi-square (for nominal
variables) tests. For non-normal continuous variables,
nonparametric methods such as Wilcoxon rank sum
test will be used. These comparisons will enable the
identification of covariates for use in later analyses for
comparing group difference. We will also perform
descriptive statistics prior to testing the hypotheses.
These analyses include means (or frequencies and pro-
portions for categorical variables) and standard devia-
tions. Care Managers’ intervention fidelity and
implementation will be examined to ensure that the
intervention protocol is followed and delivered as
intended.
Hypothesis testing will involve comparisons of two
groups. This is a longitudinal study where each patient
will be measured four times at baseline and every four
months post-baseline. Since repeated measures of the
same patient are correlated, methods for longitudinal
studies will be applied to address the dependence
among the repeated outcomes.
The longitudinal design of the study calls for analyses
of repeated-measures data. The two most popular
approaches for longitudinal data modeling are the
weighted generalized estimating equations (WGEE) and
generalized linear mixed-effects model (GLMM). Both
approaches achieve valid inference under the two popu-
lar missing data mechanisms, the missing completely at
random (MCAR) and the missing at random (MAR)
models. As WGEE does not require any distributional
assumption, it provides more robust inference than its
counterpart GLMM, WGEE will be used for estimation
of intervention effects if discrepancies between GLMM
arise.
We will model the mean response by including treat-
ment groups, time, and time by treatment group inter-
action, controlling for patients’ baseline and
demographic characteristics if the latter differentiate
treatment groups at baseline. A significant time by
group interaction will indicate differential changes
between the two groups over time. For the GLMM and
WGEE analyses, model selection procedures will be
applied to find the most parsimonious model using
Akaike’s information criterion (AIC) as a guide.
Analysis of Specific Aims
Aim 1: For primary outcome on patient level outcomes,
we hypothesize that patients in DCM practices will have
greater reduction in depression symptom severity, and
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depression, than patients who receive CAU.
We will examine changes in depression symptom
severity over time between the two treatment conditions
using the longitudinal models for continuous outcomes.
We will include as explanatory variables in the model
the treatment and time main effects plus their interac-
tion, as well as the covariates that significantly predict
treatment assignment at baseline. A significant interac-
tion will indicate a significant difference between the
two treatment conditions.
Since the remission status is assessed at 16 weeks, the
data is cross-sectional. Thus, we will test differences in
remission rates between the two treatment conditions
using logistic regression. We will include as explanatory
variables in the model the treatment condition and the
covariates that significantly predict treatment assign-
ment at baseline. Differences in this outcome between
the two groups will be indicated by a significant treat-
ment main effect.
Note that we do not expect many subjects with miss-
ing data at 16 weeks. In case the number of subjects
with missing data is large, we will model the missing-
ness using logistic regression with missing data status as
the dependent and treatment and other covariates as
explanatory variables. We will then control for the sig-
nificant explanatory variables from the missing data
model as covariates in the logistic regression for remis-
sion rates.
Aim 2: For provider level outcomes, we will examine
whether DCM are associated with greater adherence to
specific quality indicators for depression treatment. We
hypothesize that the proportion of depressed subjects
who receive an antidepressant prescription, have docu-
mented evaluation of suicide risk, and receive an
appointment for follow-up within two weeks of prescrip-
tion will be greater for the DCM group than CAU.
We will test this provider-level (or rather aggregated
patient-level) outcomes hypothesis using the longitudi-
nal models for binary outcomes discussed under the
General Considerations for Data Analysis. We will
include as explanatory variables in the model the treat-
ment and time main effects plus their interaction, as
well as the covariates that significantly predict treatment
assignment at baseline. A significant interaction will
indicate a significant difference between the two treat-
ment conditions.
Aim 3a: For provider level outcomes, we hypothesize
that providers in DCM practices will have greater
improvements in knowledge/attitudes about depression
than those are in CAU practice.
We will use the same modeling strategy for longitudi-
nal data as in Aim 1b to examine this hypothesis. Since
the provider level data being very limited given that
only a total of 16 clinics will participate in the study,
the analysis is largely descriptive, with the model esti-
mates providing information about differential improve-
ments in knowledge/attitudes about depression between
the DCM and CAU practices.
Aim 3 b: For patient level outcomes, we hypothesize
that patients in DCM practices will have greater
improvements in functioning and quality of life, greater
reduction of stigma to depression treatment, and greater
satisfaction with their care, than patients who receive
CAU.
We will use the same modeling strategy for longitudi-
nal data as in Aim 1b to examine this hypothesis. A sig-
nificant interaction will indicate a significant difference
between the two treatment conditions.
Ethical considerations
For the protection of the subject’s privacy and confiden-
tiality, we will use the following steps:
1) During the informed consent process, we will
address potential subjects’ concerns about protection of
their identities against undesired intrusions by the
research team and others (privacy) and about limiting
access to study information that might identify them
(confidentiality).
2) Subjects will be interviewed in a room within the
primary clinic or their homes in a manner that assures
their privacy. The site of the interview will be the sub-
ject’s choice.
3) In order to protect the confidentiality of subject
information, we will take a number of precautions.
These include training of research interviewers in confi-
dentiality procedures; entry and storage of data using
coded identification labels; maintenance of hard copy
data forms and project computers in locked and secure
locations with restricted access by enforced password
protection. Back-ups of all electronic study files will be
made regularly to allow for recovery of data due to disk
failure. We will minimize risks associated with subject
burden or distress by employment of research personnel
with appropriate backgrounds and experience and work
with psychological factors and elderly subjects.
The most common side effects of Sertraline are sleepi-
ness, nervousness, insomnia, dizziness, nausea, tremor,
skin rash, and upset stomach, loss of appetite, headache,
diarrhea, abnormal ejaculation, dry mouth and weight
loss. Important side effects are irregular heartbeats,
allergic reactions and activation of mania in patients
with bipolar disorder. Most common side effects will
disappear in 1-2 weeks without any treatment. In this
study, we reduce the start dose as 25 mg/d to avoid
most side effects for the concern of age and tolerance.
For important side effects, PCPs will report to psychia-
trists and let them take care of them.
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will not receive any intervention from our study team.
They consent to be recruited and be assessed with
depression and suicide risk. According to the usual care
in primary care setting in our study place, most patients
with depression have no any treatment or intervention;
some PCPs may give them some advice or refer them to
other professional institutions, a very small part of
patients may visit psychologists or psychiatrists. In our
study, all patients will be assessed with suicide risk. The
assessment of suicide risk will be based initially on the
item i (Thoughts that you would be better off dead or
of hurting yourself in some way) of the 9-item Patient
Health Questionnaire (PHQ-9). If a patient endorses
active or passive suicidal ideation (any answer except
“n o ta ta l l ”), the person administering the questionnaire
(patient’s PCP, nurse or research assessor) will follow a
standard DCM Study Safety Protocol (see the supple-
ment). That is, they will be required to ask the following
5 questions and then call the psychiatric team as speci-
fied by the Study Safety Protocol to review results an
implement interventions as indicated. The psychiatric
team will be readily available during the research period.
The five questions are:
1) In the past month, have you made any plans or
considered a method that you might use to harm your-
self? Y/N
2) Have you ever attempted to harm yourself? Y/N
3) There’s a difference between having a thought and
acting on a thought. Do you think you might actually
make an attempt to hurt yourself in the near future? Y/
N
4) In the past month have you told anyone that you
were going to take your own life, or threatened that you
might do it? Y/N
5) Do you think there is any risk that you might hurt
yourself before you see your doctor the next time? Y/N
Discussion
Since most studies focusing on collaborative care have
been conducted in the US, an important question is
whether or not the positive outcomes of this interven-
tion can be replicated in China. Based on the Chronic
Disease Management Model and the core components
from the collaborative care model for depression in
USA, some CCM trials were conducted for depression
in other countries. A randomized controlled trial in the
U n i t e dK i n g d o m( U K )h a ss h o w nt h a tt h eC C Mf o r
older people with depression, used in primary care set-
tings, was more effective than usual general practice
care and its feasibility and effectiveness were acceptable
in the UK [94]. In the Netherlands a trial emphasized
factors influencing the CCM implementation and con-
cluded that implementation depended on changes at all
levels of the PCC system [95]. The primary care setting
is a promising domain for the management of late life
depression in China, however, its effectiveness must be
tested empirically, and this research needs to be con-
ducted in Chinese primary care settings with Chinese
providers and patients.
During our preliminary investigation in Chinese pri-
mary care settings, we found that PCPs did not diagnose
and treat patients with depression. If they recognized
potential cases of depression, PCPs suggested that
patients visit mental health specialists. Currently, there
is not a transfer mechanism between PCPs and mental
health specialists (i.e., direct referrals) and most PCPs
are not aware of mental health specialists in their city.
Occasionally, PCPs prescribed antidepressants following
mental health specialists’ protocols on patients’ medical
records. Based on these preliminary data we propose
that a system-wide intervention is needed in PCCs that
will involve the collaboration of PCPs, nurses as care
managers, and psychiatrists as mental health specialists,
as well as the promotion of treatment guideline-driven
care, as a collaborative care management intervention
for depressed, older patients.
Thus, our model includes PCPs, nurses, psychiatrists,
treatment guidelines, psychiatric consultation and com-
munication as the Depression Care Management (DCM)
model for late life depression in Chinese primary care
settings. As the first randomized controlled trial of
CCM for late life depression in China, we acknowledge
that the trial intervention will not tackle all the barriers
to the integration of depression management in primary
care, and the medication treatment is not well enough
for the needs of patients. How to design an effective and
evidence-based psychotherapy for the management of
depression, how to integrate other useful resource into
the model, how to use this model in big rural area in
China, these question will be addressed in future
research. The proposed trial will provide the first sys-
t e m a t i ce v i d e n c ef o rt h ec o l l a b o r a t i v ec a r em o d e lf o r
mental health problems in late life, and will be helpful
for the government’s decision-making on the supporting
mental health program in China primary care settings.
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